P86.07 CDK12 Mutated Extensive Stage Small Cell Lung Cancer Showed an Exceptional Response to Olaparib and Paclitaxel

The poly ADP ribose polymerase (PARP) expression is significantly higher in SCLC than normal lung epithelial cells and other histologic subtypes of lung cancer. In preclinical models, the loss of function mutation of Cyclin-dependent kinase 12 (CDK12) was related to PARP inhibitor sensitivity (Bajrami et al., 2014). This mutation is found in 1.7% of SCLC (Julie et al., 2015). However, little is known about the clinical implications of CDK12 mutated small cell lung cancer.